Groundbreaking medical research completed in Hamilton

September 6, 2017 by  

Two Hamilton-based medical studies published late last month have produced policy-changing results.

Over 300 million people worldwide suffer from cardiovascular disease, with upwards of 5% to 10% having a heart attack or stroke each year. Traditional therapies have focused on the use of daily low-dose aspirin, which has produced only moderately effective results.

The Hamilton-led clinical trial into improved treatments for heart attack and strokes, included more than 27,000 patients from 33 different countries. Researchers found that when aspirin was combined with Rivaroxaban, an anticoagulant, the patient’s risk of suffering from a heart attack or stroke was lowered by 24%.

The findings were presented in Barcelona, Spain, on August 27 at the Congress of the European Society of Cardiology. At such conventions, presentation folders are often used with sophisticated graphics and images made possible by variable data printing.

The second Hamilton-led clinical trial sought to prove or dispel the current dietary guidelines that recommend lowering fat intake and increasing fruit and vegetable consumption.

This clinical trial ran for over seven years, and included 135,000 patients from 18 different countries. Researchers found that there is hardly any benefit from eating more than three to four servings of vegetables and fruit per day, and that the focus should be on the reduction of the number of carbohydrates consumed. In addition, the intake of sensible amounts of all major types of fat was found to lower the risk of heart attacks and strokes.

These findings were published in The Lancet, a reputed medical journal, on August 29.